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Abstract
Mucopolysaccharidosis type I (MPSI) is an autosomal recessive disease that leads to systemic lysosomal storage, which is
caused by the absence of a-L-iduronidase (IDUA). Enzyme replacement therapy is recognized as the best therapeutic option
for MPSI; however, high titers of anti-IDUA antibody have frequently been observed. Due to the immunosuppressant
properties of MSC, we hypothesized that MSC modified with the IDUA gene would be able to produce IDUA for a long
period of time. Sleeping Beauty transposon vectors were used to modify MSC because these are basically less-immunogenic
plasmids. For cell transplantation, 46106 MSC-KO-IDUA cells (MSC from KO mice modified with IDUA) were injected into the
peritoneum of KO-mice three times over intervals of more than one month. The total IDUA activities from MSC-KO-IDUA
before cell transplantation were 9.6, 120 and 179 U for the first, second and third injections, respectively. Only after the
second cell transplantation, more than one unit of IDUA activity was detected in the blood of 3 mice for 2 days. After the
third cell transplantation, a high titer of anti-IDUA antibody was detected in all of the treated mice. Anti-IDUA antibody
response was also detected in C57Bl/6 mice treated with MSC-WT-IDUA. The antibody titers were high and comparable to
mice that were immunized by electroporation. MSC-transplanted mice had high levels of TNF-alpha and infiltrates in the
renal glomeruli. The spreading of the transplanted MSC into the peritoneum of other organs was confirmed after injection
of 111In-labeled MSC. In conclusion, the antibody response against IDUA could not be avoided by MSC. On the contrary,
these cells worked as an adjuvant that favored IDUA immunization. Therefore, the humoral immunosuppressant property of
MSC is questionable and indicates the danger of using MSC as a source for the production of exogenous proteins to treat
monogenic diseases.
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Introduction
Mucopolysaccharidosis type I (MPSI) is an autosomal recessive
disease that leads to systemic lysosomal storage caused by the
absence of the enzyme alpha-L-iduronidase (IDUA) [1,2]. IDUA
participates in the degradation of glycosaminoglycans (GAG), and
its absence causes the accumulation of heparan sulfate and
dermatan sulfate in various tissues and organs, which causes coarse
facial features, mental retardation, skeletal abnormalities, short
stature and excess GAG in the urine [3].
Currently, with the high production capacity of the recombi-
nant IDUA enzyme, enzyme replacement therapy (ERT) has
become the best therapeutic option for MPSI. Although the cost of
treatment is very expensive (US$ 150–300 thousand per year),
patients treated weekly with this enzyme via intravenous infusion
have shown great improvement. Dramatic reduction in urinary
GAG excretion, normalization of hepatosplenomegaly and
improved respiratory function and physical capacity were the
main benefits that were observed in most patients treated by ERT
[4,5].
The IDUA in circulation is taken up by cells via mannose-6-
phosphate receptor through a mechanism known as cross-
correction. For efficient ERT, it is essential to maintain the active
catalytic site of the enzyme and that these enzymes penetrate
efficiently into deficient cells. Despite the existence of this transport
mechanism for IDUA, most MPSI patient cells have never
interacted with this enzyme. Therefore, IDUA becomes a foreign
body that can generate an immune response. In clinical studies of
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lysosomal storage diseases (LSD) by ERT, alloantibodies were
generated in all LSD [4,5]. The initial clinical studies of ERT for
MPSI reported that approximately 40% of patients generated
specific antibodies against IDUA, but immunoprecipitation of the
enzyme or inhibition of its catalytic activity were not observed [6].
However, a posterior, multinational prospective study showed that
patients with a high-titer antibody response showed sub-optimal
therapeutic effects when compared to patients who did not have
this response [7]. In another study, 91% patients were positive for
alloantibodies, but the neutralizing effect of these antibodies
against IDUA was unknown [8]. The consequences of these
immune responses may affect treatment and could lead to rapid
disease progression and subsequent early death [5].
Mesenchymal stem cells (MSC) are able to differentiate into
osteocytes, chondrocytes, adipocytes and other cells and are
capable of proliferation and adhesion to plastic, which facilitates
their cultivation and expansion in large quantities [9]. The main
sources of MSC are bone marrow and adipose tissue, but it is
known that virtually all tissues possess MSC [10]. One of the
properties of MSC is their capacity for secreting immunosuppres-
sive molecules such as nitric oxide [11,12], prostaglandins,
indoleamine 2,3-dioxygenase and IL-6 [13].
The immunosuppressant effects of MSC upon T cells, natural
killer cells, dendritic cells and macrophages have been widely
studied [14,15,16,17]. Although the immunomodulatory activities
of MSC upon B cells are still controversial, strong evidence
suggests a delay in B cell maturation and antibody production by
MSC in mice [18,19] and human cell culture [20,21]; however,
their interaction in vivo is still not well known.
Because the antibody generation against IDUA is a serious
problem when treating MPSI patients with ERT and based on the
immunosuppressive property of MSCs, we hypothesized that
MSCs modified with an IDUA gene can constitutively produce
IDUA because the MSCs could decrease or avoid the generation
of anti-IDUA antibodies. To test this hypothesis, we modified
MSC with a Sleeping Beauty transposon (SB) vector expressing the
human IDUA gene to constantly provide IDUA in vivo and
injected these cells into the peritoneum of IDUA knockout mice
and wild-type mice. The production of anti-IDUA antibodies and
IDUA were monitored for weeks to evaluate our hypothesis.
In this study, we used the SB system for gene transfer because it
is an integrative, non-viral vector and therefore it is expected to
bring about long-term gene expression and an immune response
against the vector should be minimal because this system is




All procedures involving animals were performed with the
approval of the Research Ethics Committee of the Federal
University of Sa˜o Paulo, Brazil (Approval number: CEP 1278/07).
IDUA knockout mice (KO) [2] were kindly provided by Dr.
Elizabeth Neufeld (UCLA, Los Angeles, USA) and were main-
tained in our animal house by breeding heterozygous animals
(HT). Two-month-old KO mice served as sources for MSC culture
establishment; four-month-old KO mice were used for in vivo
experiments; and three-month-old C57BL/6 mice (WT) were
purchased from INFAR (National Institute of Pharmacology, Sa˜o
Paulo, Brazil) for MSC culture establishment and in vivo
experiments.
Vectors’ construction
The cDNA encoding the human IDUA gene was excised from
the pTiger vector [22] using HindIII and inserted in the uP [23] or
pVAX vectors (Invitrogen San Diego, CA, USA) for uP-IDUA
and pVAX-IDUA construction, respectively. The uP vector
contains the complete CMV promoter with enhancer sequences,
and the pVAX vector only contains the minimum CMV promoter
sequence. For pT2-CMVi-IDUA and pT2-IDUA, the expression
cassettes were excised from uP-IDUA and pVAX-IDUA, respec-
tively, using NruI and XhoI and then inserted in the EcoRV site of
pT2-BH vector (kindly provided by Dr. Perry B. Hackett of the
University of Minnesota, USA). The pT2-CAGGS-IDUA vector
promotes IDUA expression by the hybrid CAGGS promoter,
which was kindly provided by Dr. Elena Aronovich of the
University of Minnesota, USA. The pCMV-SB11 and pCMV-
DDDE vectors express SB transposase or SB transposase without a
catalytic domain, respectively. These vectors were kindly provided
by Dr. Perry B. Hackett of the University of Minnesota, USA. The
pCMV-SB100X vector was kindly provided by Dr. Zsuzsanna
Izsva´k and Dr. Zolta´n Ivics from the Max-Delbru¨ck-Center for
Molecular Medicine, Berlin, Germany.
Mesenchymal stem cells culture and nucleofection
The KO and WT mice were euthanized by cervical dislocation
to obtain mesenchymal stem cells (MSC-KO and MSC-WT,
respectively) by flushing the bone marrow of the femur and tibias.
Technologies, Carlsbad, USA) supplemented with 10% fetal
bovine serum (Life Technologies), 2 mM glutamine (Life Tech-
nologies), 50 units/ml penicillin and 50 mg/ml streptomycin
sulfate (Life Technologies). The osteogenic and adipogenic
differentiation were performed based on an established protocol
[22]. After five passages, plasmid delivery was carried out by
nucleofection with 10 mg total vector (proportion of the shuttle
vector and the SB transposase vector were 1:1 (w/w)) using the
human MSC Nucleofector kit (Lonza, Basel, Switzerland) and
program U-23.
MSC transplantation
The KO and WT mice were treated with 80 mg/kg of
isosorbide mononitrate by gavage two hours previous to the
procedure. MSC-KO and MSC-WT were nucleofected with the
pT2-CAGGS-IDUA and pCMV-SB100X vectors (MSC-KO-
IDUA and MSC-WT-IDUA, respectively) and were expanded for
15 days. Four million cells were diluted in 4 ml of DMEM and
were injected into the peritoneum of each mouse.
a-L-Iduronidase enzyme assay
In vitro IDUA dosage was performed using a previously
described protocol [22] that utilized 4-methylumbelliferyl-a-L-
iduronide (Glycosynth, UK) in fluorometric assays. The IDUA
activity from plasma was determined using protocols described by
Aronovich et al. [24], and enzymatic activity was expressed as
nmol of 4-methylumbelliferone that were released per mg tissue
protein per hour (U/mg) or per ml plasma per hour (U/ml).
Measurement of anti-IDUA antibody
The presence of human anti-IDUA antibody was determined
using a method described by Di Domenico et al. [25]. Blood
samples were collected fifteen days after the third injection,
centrifuged at 5006g/5 min and diluted in 0.1% BSA/PBS. Fifty
microliters of diluted serum was then used for the Enzyme-linked
immunosorbent assay (ELISA) reaction.
Stem Cells Do Not Prevent Antibody Response
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Histological analysis
The tissues were fixed in 4% paraformaldehyde for 48 hours,
dehydrated and embedded in paraffin. Sections of 4-mm thickness
were obtained and stained with hematoxylin-eosin (HE) to
determine the degree of tissue regeneration and the presence of
adipocytes and infiltrated cells. Images were obtained using an
optical microscope (Olympus BX60) and analyzed digitally [26].
111In-labeled MSC distribution
The MSC-KO was cultivated in the previously described
conditions. Three million cells were incubated with 10 mCi of
111In-oxine for 30 minutes at 37uC. 111In-labeled MSC were
injected intraperitoneally into six 3-month-old WT mice. Two,
four and twenty-four hours after injection, these mice were
euthanized by cervical dislocation and the tissues were collected
and weighed. The 111In-oxine level was measured using the 1282
Compugamma program (LKB Wallac, Gaithersburg, Md.), and
the radioactivity in each organ was expressed in two ways: by the
counts per unit mass and as a percentage of the injected dose. In
all cases, the radioactive decay of 111In was corrected to the time of
injection. Differences in the radioactivity of the measured organs
were determined using analysis of variances (ANOVA) at a
threshold of p= 0.05 to indicate a statistical significance.
Cytokines measurement
The GM-CSF, IFNc, TNFa, IL-2, IL-4, IL-5, IL-10 and IL-12
in treated KO mice serum from MSC-KO-IDUA (n= 3) and non-
treated KO mice (n = 2) were measured fifteen days after the third
cell injection using a Bio-Plex Pro Mouse Cytokine 8-Plex panel
(Bio-rad, Hercules, CA) in Luminex and analyzed using the Bio-
Plex Manager 6.0 software (Bio-rad).
Intramuscular immunization plus Electroporation in vivo
Using a 1 ml insulin syringe, 50 mg of plasmid DNA in 50 ml of
PBS was delivered into each of the quadriceps muscles of the mice
(25 mg pT2-CAGGS-IDUA plus 25 mg pCMV-SB100 or pCMV-
DDDE per mouse). Immediately after the DNA injection,
electroporation was performed using a needle electrode of
0.5 cm needles of 0.5 mm thickness and with a 5 mm distance
between them. Three electric pulses (field strength = 100 V/cm;
pulse length = 50 ms; ECM 830 field generator, BTX Division,
Genetronix, San Diego, CA, USA) were delivered at 1 s of
intervals [27].
Results
Characterization of MSC and in vitro IDUA gene
expression
MSC were established according to the culture criteria that
were described previously. The MSC-KO were maintained in
culture for up to 40 passages without morphological changes or
differentiation potentials in osteocytes and adipocytes (Figure 1).
To obtain a large amount of IDUA-producing MSC, the MSC-
KO were nucleofected with the following plasmids: pT2-CMVi-
IDUA, pT2-IDUA and pT2-CAGGS-IDUA (Figure 2). For vector
integration, the MSC were nucleofected with pCMV-SB100X,
and pCMV-SBDDDE (Figure 2) was used as a negative control
because this vector did not express the SB transposase. All
transfected cells produced IDUA after three days, ranging from
10 U/mg to 100 U/mg (Figure 3), but MSC transfected with
pCMV-SB100X and pT2-CAGGS-IDUA maintained the initial
level of IDUA throughout the 30-day follow-up (Figure 3). The
control without transposase (pT2-CAGGS-IDUA and pCMV-
DDDE) decreased the expression of IDUA over time because no
gene integration occurred. After 3 days, the activity of transfected
IDUA cells with pT2-CAGGS-IDUA and pCMV-SB100X
quadrupled (105654 U/mg to 429698 U/mg). These IDUA-
producing cells were frozen. The IDUA activity remained above
300 U/mg for 365 days after nucleofection (Figure 3). Based on
these data, MSC modified with the pT2-CAGGS-IDUA and
pCMV-SB100X (MSC-KO-IDUA) plasmids were used for
therapy in KO mice.
MSC biodistribution
To determine the biodistribution of the injected MSC, the MSC
were radiolabeled with Indium-111 that was conjugated to oxine,
injected into the peritoneum of the mice, and the organs were
isolated for radioactivity counting. Two hours after MSC
injection, radioactivity was detected in the spleen, stomach, large
and small intestines, liver and kidney; and 24 hours later, the
profile of radioactivity distribution was quite similar to that of
2 hours after injection (Figure 4). The highest radioactivity was
found in the spleen and was statistically significant.
MSC transplantations and antibody responses
For the first MSC-KO implantation, the cells were nucleofected
with pT2-CAGGS-IDUA and pCMV-SB11, and 46106 of these
cells that were suspended in 4 ml were injected into the
peritoneum of 4-month-old KO mice. These mice produced
28.8658.7 U/mg of IDUA per mouse, and the final volumes and
protein concentrations of the crude extracts were usually 1 ml and
3 mg/ml, respectively; therefore, at the moment of cell injection,
these cells were producing approximately 9.6 U of IDUA. Taking
into account that a mouse weighing 25 g contains approximately
2 ml of blood, the initial IDUA activity of the MSC-transplanted
mouse should be approximately 4.8 U, which corresponds to the
activity of a wild-type mouse [22]. Therefore, if this cell
transplantation worked as expected, the IDUA activity in the
blood would be measurable and the KO mice could be treated.
However, after more than a month of follow-up, IDUA activity
was not observed in any mouse (Figure 5A). During this
Figure 1. Differentiation and characterization of MSC-KO
cultures derived from IDUA-KO mice. MSC-KO cells were
differentiated into osteoblasts (upper panel) and adipocytes (lower
panel) before (A) and after nucleofection (B, C). Deposits of fat and
calcium, which are characteristic of adipocytes and osteoblasts,
respectively, are stained in yellow and red, respectively. The original
magnification is 1006, and the bars correspond to 50 mm.
doi:10.1371/journal.pone.0092420.g001
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experiment, three mice died during the cell transplantation and
blood sampling.
One month after the first cell transplantation, these animals
were treated again with 46106 MSC that were modified with
SB100X, which produced 359.226108.16 U/mg. Based on the
same calculation as before, we conclude that 120 U was injected
into the peritoneum, and this value was 12-fold higher than what
was used in the first transplantation. In this experiment, two new
KO mice were included for comparison with the other ongoing
mice. One day after cell transplantation, more than 1 unit of
IDUA activity was present in the blood of the three mice, which
represented about a half of the activity of heterozygous mice
(Figure 5B). Two more treated mice had slightly elevated IDUA
activities, but these values were not statistically significant.
However, these IDUA activities decayed soon later, and only
two of them had some activity on the 10th day. In the three mice
that had higher IDUA activity, one had received MSC-KO-IDUA
for the first time, and another new mouse had IDUA activity but
its level was low. These results indicated that the transplanted cells
could not adapt in the peritoneum and died soon after injection, or
the IDUA produced by the transplanted cells were quickly
captured by host cells, or the IDUA was neutralized by antibodies.
In addition, the first cell transplantation apparently did not cause
immunization or tolerance. After the second cell transplantation,
two more mice died because of MPSI disease evolution.
When these mice reached approximately 6-months-old, the
third injection of MSC-KO-IDUA was carried out with the
intention of reverting, at least partially, the disease progression. At
this time, we injected the same number of cells, but they produced
more IDUA activity: 530.66659.72 U/mg, which represents an
injection of 179 U. The six-month-old KO mice were used to be
weakened because of disease progression; consequently, any
treatment in this stage was a challenge. After a week of follow-
up, we did not detect any IDUA activity in these mice (Figure 5C).
Figure 2. Schematic vector diagrams. CMV: minimum human
cytomegalovirus promoter; CMVi: complete human cytomegalovirus
promoter; CAGGS: chicken b-actin promoter with CMV enhancer; IDUA:
human IDUA cDNA; pA: polyadenylation signal; IR L: left inverted
repeated sequence; IR D: right inverted repeated sequence; SB100X:
Sleeping Beauty 100X; DDDE: Mutated Sleeping Beauty without
transposase activity.
doi:10.1371/journal.pone.0092420.g002
Figure 3. IDUA production by MSC-KO modified with IDUA-expressing vectors. IDUA activity of all nucleofected cells were monitored for
30 days, except for the pT2-CAGGS-IDUA + pCMV-SB100X nucleofected cells, which were monitored for one year. *p,0.0001 for the pT2-CAGGS-
IDUA+pCMV-SB100X group compared to other groups. A two-way ANOVA with the Bonferroni post hoc test was used. Vector descriptions are in the
Methodology section.
doi:10.1371/journal.pone.0092420.g003
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However, surprisingly, these mice presented a high titer of anti-
IDUA antibody (Figure 5D), which was observed after 15 days of
the third cell transplantation.
To evaluate the antibody response that was generated against
IDUA in the MSC-KO, the same cell transplantation procedure
was performed using a MSC-WT that was modified with the same
vectors to express IDUA. In this step, we used the MSC-WT to
eliminate any interference from the IDUA mutation in the
immunosuppressant property of MSC. The MSC-WT-IDUA
produced 461.55652.05 U/mg, which corresponded to 154 U
before injection into the peritoneum. Therefore, these values were
very similar of those that were used in the previous MSC-KO-
IDUA transplantation. After two weeks of cell transplantation,
anti-IDUA antibody was detected in all mice and was present until
the last assay, which occurred on the 98th day (Figure 6A). The
antibody titer of the mice transplanted with MSC-WT-IDUA
without SB was only half of that from mice transplanted with
MSC-WT-IDUA with SB, which indicated that long-term antigen
expression induced a stronger antibody response. Antibody titer
decays occurred on the 43rd and 52nd days for unknown reasons,
but these levels later returned to normal in both groups. These
results clearly demonstrate that MSC did not suppress the
antibody response against IDUA.
To understand the immunogenicity of IDUA, WT mice were
transfected with the same vectors by electroporation. Electropo-
ration was adopted here because this method brought about better
immunization [27]. The antibody response began about a week
later than that of the MSC-IDUA transplantation (Figure 6B), but
the antibody titer was similar (OD 490 nm<10), and this level was
maintained until the 40th day, which was the day of the last
antibody titration.
As the final experiments, the MSC- KO- IDUA treated mice
were killed and their organs were analyzed by histology. Among
the changes observed, we found inflammatory infiltrate in the
renal glomeruli, thickening of the Bowman’s capsule, reduction of
the lumen of the renal tubules and replacement of normal tissue by
inflammatory infiltrate in the renal medulla (Figure 7A). These
histological alterations are typically observed in kidneys during the
filtration of immune complexes, which are formed by antigens and
antibodies. Therefore, this evidence also supports the previous
results that indicate that antibody responses were increased by
MSC-KO-IDUA or MSC-WT-IDUA transplantations.
The cytokine profiles of MSC-KO-IDUA-treated mice were
then analyzed using blood samples that were collected 15 days
after the last cell transplantation, and the non-treated WT mice
were used as a control. Among the analyzed cytokines, only TNF-
alpha was present in MSC-KO-IDUA-treated mice and was 5-fold
higher than that of the control group (Figure 7B), which indicated
a state of inflammation in these mice.
Discussion
Monogenic diseases are of great interest for gene therapy studies
because these diseases currently have no effective treatment. MPSI
patients must have a constant supply of IDUA to relieve disease
manifestation, and this can be performed by enzyme replacement
therapy. It has been observed that anti-IDUA antibodies can be
generated by ERT [4,5,6,7,28,29], and such an antibody response
is somewhat expected because the IDUA is a new protein in these
patients. However, in animal models, it was shown that ERT or
gene therapy started at birth could overcome partially antibody
response and improve outcome in difficult-to-treat organs
[30,31,32]. Based on the immunosuppressant properties of MSC
[11,12,13,14,17,20,21], we hypothesized that the production of
IDUA by these cells could avoid the antibody response and
become a long-term IDUA producer.
The SB system has been proven to be efficient to gene transfer
and long-term gene expression in many mammalian cells,
including MSC [33]. Here, we showed that this system is also
efficient in modifying MSC-KO by nucleofection (Figure 2)
because IDUA gene expression has remained nearly constant for a
year with the same level as observed initially. The increased IDUA
activity during the first week was likely due to continuing
integration activity by the SB100X transposase, which led to
multiple gene copy integrations per cell [33] and/or by high
SB100X activity during the first week after nucleofection [34]. In
addition, the property of differentiating into osteocytes and
adipocytes (Figure 1) was maintained after transfection, which is
an important characteristic of these cells [9,10,35].
Because MPSI is a monogenic disease that affects all patient
cells, an ideal therapy should be one that could provide IDUA to
all affected cells, but this practice is not feasible at this moment.
The peritoneum is a highly vascularized region that is easy to
Figure 4. Biodistribution of MSC after injection into the
peritoneum. MSC were labeled with 111In before injection, and
radioactivities in the isolated organs were counted 2 (A) and 24 hours
(B) later. Five and three mice were used for 2- and 24-hour experiments,
respectively. * p,0.05 when comparing the spleen to all other tissues. A
one-way ANOVA with the Bonferroni post hoc test was used.
doi:10.1371/journal.pone.0092420.g004
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access; therefore, a large volume of MSC can be injected. These
injected cells can rapidly traffic to affected organs, such as the
liver, spleen and kidneys, because of its proximity to these organs.
In addition, secreted IDUA will circulate easily and provide this
enzyme to the body. The ability for MSC trafficking through the
peritoneum is not clearly known, but because macrophages are
located in this space and they can traffic through other organs
[36,37], it is expected these cells have a similar mobility. To
monitor the mobility of MSC through the peritoneum, radiola-
beled MSC were injected into the peritoneum, and the organs
were removed later to quantify radioactivity. The vessel dilator
isosorbide mononitrate was administered before cell injection to
enhance cell trafficking through the peritoneum. White-blood-cell
labeling with 111In-oxine is a well-known procedure for analyzing
infection and inflammation in animals and humans [38,39].
Because 111In-oxine is a neutral molecule, it can easily penetrate
the cell membrane, thus allowing 111In to attach to an intracellular
component such as lactoferrin [40] and causing 8-hydroxyquino-
line to be released by the cell. The exchange of 8-hydroxyquino-
line by an intracellular component only occurs if the intracellular
component can form a more stable complex; therefore, it is
expected that the labeled MSCs can hold 111In until their death.
Because our biodistribution experiments lasted only 24 hours, we
expected that only a minimum number of MSC would die. In
addition, because the half-life of this radioactivity is 2.8 days,
counting the radioactivity 24 hours after injection will provide
reliable radioactivity counting because the remaining activity at
this time would be approximately 80% of the initial value. Under
these experimental conditions, we observed that the spleen was the
main organ that received the injected MSC. However, the
stomach, kidneys and intestine, which are adjacent to the
peritoneum, also had high radioactivity (Figures 4A and 4B). In
addition, the basal radioactivity found from the peritoneum and
Figure 5. IDUA and anti-IDUA antibody production after MSC-KO-IDUA transplantation. For the first transplantation (A), four million MSC-
KO cells were nucleofected with pCMV-SB11 and pT2-CAGGS-IDUA and transplanted into the peritoneum. Three mice died during this experiment:
88.1.2, 88.1.5 and 89.1.3. Approximately, 40 days after the first cell transplantation, the second transplantation was performed using MSC-KO that
were nucleofected with pCMV-SB100X and pT2-CAGGS-IDUA (B). Here, two new IDUA-KO mice were included (#). A month after the second
transplantation, a third transplantation was performed using the same procedure as the second (C). Fifteen days after the last cell transplantation,
blood samples were collected to quantify the anti-IDUA antibody (D). *p,0.05 when comparing the IDUA-KO group to other groups. A two-way
ANOVA with the Bonferroni post hoc test was used. HT: heterozygous mouse. KO: IDUA-KO mouse.
doi:10.1371/journal.pone.0092420.g005
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the intraperitoneum fluid 2 hours after injection indicates high
mobility of MSC from the peritoneum to circulation.
These data indicate that the distribution of the MSC-KO-
IDUA through the body by intraperitoneal injection was an easy
and productive procedure.
To test the hypothesis that MSC modified with IDUA could
become a good, long-term source of IDUA in vivo because of the
immunosuppressant properties of MSC, four million MSC-KO-
IDUA were injected into the peritoneum three times over one-
month intervals. In an attempt to minimize the immune response,
MSC were modified with SB11 to produce a low level of IDUA
and were used in the first injection, and for the second and third
injections, they were modified with SB100X to produce high levels
of IDUA. Considering that the total blood volume of a mouse
weighing 25 g is approximately 2 ml, the expected IDUA activities
in the blood after injections are 4.8, 60 and 90 U/ml for the first,
second and third injections, respectively. Therefore, the units
produced by the first injection are similar to that produced by a
wild-type mouse (462.5 U/ml) [24,31,41], and the units produced
by the other injections are well above this level and are
comparable to human patient submitted to ERT [6,28]. However,
no enzyme activity was detected after the first injection and only a
small peak of IDUA production (less than 2 U/ml) was observed
one day after the second injection, but this level was not sustained
days later (Figures 5A and 5B). To verify the low production of
IDUA after MSC-KO-IDUA administration, a third injection was
carried out using MSC-KO-IDUA, which produced high IDUA
activity; however, no enzymatic activity was detected in any of the
mice (Figure 5C). Unlike IDUA activity, these MSC-KO-IDUA-
treated mice presented high titers of anti-IDUA antibody
(Figure 4D), high concentration of TNF-alfa (Figure 7B) and
damaged cortical and medullar kidney tissue (Figure 7A). These
results led us to doubt that the immunosuppressant property of
MSC from KO mice could be lost or reduced due to IDUA gene
mutation or GAG accumulation in MSC. To better investigate
this question, MSC-WT was transfected with IDUA and injected
in WT mice following the same protocol that was used in the KO
mice. In this experiment, no IDUA was detected, but the human
anti-IDUA antibody was detected on the 13th day after MSC
injection and reached its highest titer on the 21st day (Figure 6A).
This antibody response was faster than the classic DNA
immunization by electroporation [27] that was at the 21st day
and reached its highest point on the 34th day after immunization
with a similar optical density (Figure 5B). Taking into consider-
Figure 6. Anti-IDUA antibody production after MSC-IDUA transplantation or electroporation with plasmid vectors. MSC from wild-
type mice (C57/Bl6) were nucleofected with pCMV-SB100X and pT2-CAGGS-IDUA and transplanted into the peritoneum of wild-type mice (n = 6 per
group) following the same procedure that was used for the KO mice (A). In the negative control group, pT2-CAGGS-IDUA and pCMV-DDDE were
used. For DNA immunization, pT2-CAGGS-IDUA with pCMV-SB100X or with pCMV-DDDE vectors were injected into the thighs of the mice and
underwent electroporation (n = 5 per group). A two-way ANOVA with Bonferroni post hoc test was used.
doi:10.1371/journal.pone.0092420.g006
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ation that the human and murine IDUA have approximately 80%
protein homology, it was surprising to have an antibody response
within two weeks that lasted more than 100 days in some animals
after only a single injection (Figure 6A). This experiment does not
provide information about the preservation of the immunosup-
pressant property of MSC-KO; however, it clearly shows that
these MSC do not suppress human anti-IDUA antibody
generation, as was expected. In addition, the antibody responses
that were generated after in vivo transfection of WT mice with
IDUA vectors by electroporation, which produced a similar level
of mice that were transplanted with MSC-WT-IDUA or MSC-
KO-IDUA, indicated that the participation of MSC in immuno-
suppression should be minimum.
The immunosuppressant activity of MSC in vivo seems to be
controversial. For example, the treatment of the autoimmune
disease Systemic Lupus Erythematosus (SLE) with bone marrow
MSC increased the survival and decreased the level of circulating
anti-dsDNA [42]. A similar result was observed in a NZBxNZW
F1 mouse model that was treated with MSC from adipose tissue
for disease prevention. However, the therapeutic effect was lost
when the treatment began after disease onset [43], the survival
time did not increase, and the formation of the anti-dsDNA
antibody could not be avoided [44]. Therefore, more in vivo
experiments will be necessary to better define the immunosup-
pressant or proinflammatory role of MSC.
In conclusion, our in vivo study with MSC modified to
constitutively produce IDUA showed an unexpected adjuvant
effect of MSC for immunization, which raised high titers of an
anti-IDUA antibody. This antibody response was as strong as
DNA immunization by electroporation and lasted longer. There-
fore, the use of genetically modified MSC for the long-term
production of IDUA in KO mice to treat MPSI still faces
unavoidable antibody responses. Our studies have been carried
out in a murine model using the human IDUA gene, but the use of
human MSC as a source for production of exogenous proteins to
treat monogenic diseases must be well validated before it is
clinically applied.
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Figure 7. Postmortem analyses of IDUA-KO mice treated with MSC-KO-IDUA by histology and cytokine production. Kidneys from
three treated mice were stained with Hematoxylin-Eosin (A). Inflammatory infiltrate in the cortex (*), replacement of normal tissue by inflammatory
infiltrate in the renal medulla (R), thickening of the Bowman’s capsule (???) and reduction of the lumen of the renal tubules (x) were marked in the
figure. Cytokine production was then evaluated using blood samples from the three treated and two non-treated mice 15 days after the last cell
transplantation (B). Only TNF-alpha was detected in the treated mice. *p,0.0001 by the paired student t-test.
doi:10.1371/journal.pone.0092420.g007
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